已收盤 11-20 16:00:00 美东时间
+0.010
+0.15%
Avalo Therapeutics granted inducement equity awards, including nonstatutory stock options for 52,000 shares, to three new employees. The options, exercisable at $6.70 per share, vest 25% after one year and monthly over 36 months. Avalo focuses on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, advancing its lead candidate abdakibart in a phase 3 program for hidradenitis suppurativa and developing AVTX-010, a next-generation ...
11-20 21:00
今日重点评级关注:瑞银:维持Liberty Media"中性"评级,目标价从110美元升至1116美元;杰富瑞:维持伊诺维奥制药"买入"评级,目标价从3美元升至8美元
11-09 14:00
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $22 to $20.
11-07 00:55
Avalo Therapeutics announced that its management will participate in two investor conferences: the Guggenheim Healthcare Innovation Conference on November 9, 2026, and the Stifel 2026 Healthcare Conference on November 10, 2026. Both events will feature fireside chats. The company is focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, with its lead candidate, abdakibart, advancing into a phase 3 p...
11-02 21:00
今日重点评级关注:摩根士丹利:维持西部数据"超配"评级,目标价从643美元升至668美元;摩根大通:维持西部数据"超配"评级,目标价从600美元升至650美元
10-26 12:30
Guggenheim analyst Yatin Suneja downgrades Avalo Therapeutics (NASDAQ:AVTX) from Buy to Neutral.
10-23 23:05
Avalo Therapeutics shares are trading lower. AbbVie reported Phase 3 INTREPID results for Lutikizumab and the company's Adbakibart is a competing treatment for Hidradenitis Suppurativa.
10-23 00:27
Fate Therapeutics appoints Jamie Harrell to its executive leadership team, leveraging his 25+ years of commercial experience in autoimmune therapies. Harrell will lead the commercial strategy for FT819 and FT839, advancing their development in autoimmune diseases like lupus nephritis and rheumatoid arthritis. His expertise in launching first-in-class therapies and expanding CAR T-cell access to community settings will support Fate's mission to tr...
10-12 11:00
Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vie...
09-23 19:07
Avalo Therapeutics will present two late-breaking studies on its anti-IL-1β antibody, Abdakibart, for moderate to severe hidradenitis suppurativa (HS) at the EADV Congress 2026 in Vienna. The Phase 2 LOTUS trial's efficacy and safety data will be highlighted in an oral presentation by Dr. Martina Porter on October 1 and a poster presentation on September 30. Avalo is advancing Abdakibart into a Phase 3 program for HS, a chronic inflammatory skin ...
09-23 11:00